

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Ramakrishnan et al.** )  
 )  
Application No. **Not assigned** ) Group Art Unit: **Not assigned**  
 )  
Filed: **February 5, 2001** ) Examiner: **Not assigned**  
 )  
For: **Transgenic Animals Having A Modified** )  
**Glycoprotein V Gene** )

Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Prior to examination, please amend this application as follows:

In the specification:

Please amend the specification as follows:

Page 1, please delete lines 7-9 and insert therefor --This application is a continuation of international application PCT/US99/17594 filed August 4, 1999 which claims priority to U.S. provisional patent application 60/109,797 filed August 4, 1998 the disclosures of which are herein incorporated by reference in their entirety.--

Page 18, line 5, delete "GG5ATGAC5GT5(CT)T5CA(GA)CG" and insert --GGCATGACCGTC(CT)TGCA(GA)CG--

Page 18, line 8, delete "GA(CT)AA(AG)ATGGT5(CT)T5(CT)T5GA(GA)CA" and insert --GA(CT)AA(AG)ATGGTG(CT)TC(CT)TGGA(GA)CA--

Page 18, line 11, delete "CC(CT)GG(CGA)AC(AC)TT(TC)AA(CT)GA(CT)(CT)T5GT(GC)AA" and insert --CC(CT)GG(CGA)AC(AC)TT(TC)AG(CT)GA(CT)(CT)TGAT(GC)AA--

Page 18, line 14, delete "Non-coding Sequence" and insert --Complements of Portions of the Human GP V Coding Sequence--

Page 18, line 16, delete "corresponds to human GP V noncoding sequence" and insert --corresponds to the complement of the human GP V sequence encoding--

Page 18, line 18, delete "GGCCA5A(AG)(TG)CC(AG)CA(AG)TC(AG)CA5A(AG)CCA(AG)GG" and insert

--GGCCCCA(AG)(TG)CC(AG)CA(AG)TC(AG)CAGA(AG)CCA(AG)GA--


Page 18, line 19, delete "corresponds to human noncoding" and insert --corresponds to the complement of the human GP V sequence encoding--

**REMARKS**

The amendment above is to correct inadvertent errors in original sheet number 18. Support for the above amendment can be found on page 17, lines 24-26 and page 18, line 1 which state that the degenerate primers are based on the sequence of human GP V shown in Figure 3 of the present application. The sequences in lines 5, 8, and 11 (SEQ ID NO: 1, 3 & 5) have been amended so that they correctly encode the corresponding amino acid sequences, SEQ ID NO: 2, 4 & 6, respectively. The sequence in line 18 (SEQ ID NO: 9) has been changed so that the sequence is complementary to the portion of the human GP V sequence encoding SEQ ID NO: 10. No prohibited new matter has been added by the above amendments.

Dated: **February 5, 2001**  
Morgan, Lewis & Bockius LLP  
Customer No. **009629**  
1800 M Street, N.W.  
Washington, D.C. 20036  
202-467-7000

Respectfully submitted  
**Morgan, Lewis & Bockius LLP**

  
Elizabeth C. Weimar  
Registration No. 44,478